Serie de casos de pacientes con hepatocarcinoma tratados con sorafenib como terapia puente a quimioembolización y finalmente como paliativo

If chemoembolisation has to delayed, it is feasible to use sorafenib as a bridging therapy, which can also serve to avoid delay in palliative therapy if the patient turns out not to be a candidate for local therapy.